肿瘤标志物：生物标志物驱动研究和统计分析中的复杂性。
Biomarkers in Oncology: Complexities in Biomarker-Driven Studies and Statistical Analysis.
机构信息
Division of Population Sciences, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Division of Biostatistics, Department of Data Science, Dana-Farber Cancer Institute, Boston, MA.
出版信息
JCO Precis Oncol. 2024 Jul;8:e2400358. doi: 10.1200/PO.24.00358.
Abstract
Biomarker-driven trials are key for precision oncology but challenge design and analysis.
摘要
生物标志物驱动的试验是精准肿瘤学的关键，但挑战了设计和分析。
相似文献
1
Biomarkers in Oncology: Complexities in Biomarker-Driven Studies and Statistical Analysis.肿瘤标志物：生物标志物驱动研究和统计分析中的复杂性。
JCO Precis Oncol. 2024 Jul;8:e2400358. doi: 10.1200/PO.24.00358.
2
Artificial intelligence entering the pathology arena in oncology: current applications and future perspectives.人工智能进入肿瘤病理学领域：当前应用与未来展望。
Ann Oncol. 2025 Apr 28. doi: 10.1016/j.annonc.2025.03.006.
3
The present and future of precision oncology and tumor-agnostic therapeutic approaches.精准肿瘤学与肿瘤非特异性治疗方法的现状与未来。
Oncologist. 2025 Jun 4;30(6). doi: 10.1093/oncolo/oyaf152.
4
The Society for Immunotherapy of Cancer Perspective on Liquid Biopsy and Radiomics Based Technologies for Immuno-Oncology Biomarker Discovery and Application.癌症免疫治疗协会关于基于液体活检和放射组学技术用于免疫肿瘤学生物标志物发现与应用的观点
Clin Cancer Res. 2025 Apr 8. doi: 10.1158/1078-0432.CCR-24-3791.
5
Pioneering the implementation of a precision oncology strategy in Portugal: the Precision Oncology Platform trial.在葡萄牙率先实施精准肿瘤学策略：精准肿瘤学平台试验。
Acta Oncol. 2024 Jun 23;63:482-486. doi: 10.2340/1651-226X.2023.33322.
6
Precision Oncology Clinical Trials: A Systematic Review of Phase II Clinical Trials with Biomarker-Driven, Adaptive Design.精准肿瘤学临床试验：基于生物标志物驱动、适应性设计的 II 期临床试验的系统评价。
Cancer Res Treat. 2024 Oct;56(4):991-1013. doi: 10.4143/crt.2024.128. Epub 2024 May 7.
7
New clinical trial designs in the era of precision medicine: An overview of definitions, strengths, weaknesses, and current use in oncology.精准医学时代的新型临床试验设计：定义、优势、劣势及在肿瘤学中的应用概述。
Cancer Treat Rev. 2019 Feb;73:20-30. doi: 10.1016/j.ctrv.2018.12.003. Epub 2018 Dec 11.
8
Multi-Institutional Evaluation of Interrater Agreement of Biomarker-Drug Pair Rankings Based on the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) and Sources of Discordance.基于分子靶点临床可操作性的ESMO量表（ESCAT）对生物标志物-药物配对排名的评估者间一致性及不一致来源的多机构研究
Mol Diagn Ther. 2025 Jan;29(1):91-101. doi: 10.1007/s40291-024-00748-4. Epub 2024 Oct 5.
9
Precision Oncology Program (POP), an observational study using real-world data and imaging mass cytometry to explore decision support for the Molecular Tumor Board: study protocol.精准肿瘤学项目（POP），一项利用真实世界数据和成像质谱流式细胞术探索为分子肿瘤委员会提供决策支持的观察性研究：研究方案。
BMJ Open. 2025 Mar 26;15(3):e096591. doi: 10.1136/bmjopen-2024-096591.
10
Trends in the use and role of biomarkers in phase I oncology trials.生物标志物在肿瘤学I期试验中的应用趋势及作用
Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6719-26. doi: 10.1158/1078-0432.CCR-06-2860.
本文引用的文献
1
Biomarker-Driven Oncology Trial Design and Subgroup Characterization: Challenges and Potential Solutions.基于生物标志物的肿瘤学临床试验设计和亚组特征分析：挑战与潜在解决方案
JCO Precis Oncol. 2024 Jun;8:e2400116. doi: 10.1200/PO.24.00116.
2
Regression models for average hazard.平均风险的回归模型。
Biometrics. 2024 Mar 27;80(2). doi: 10.1093/biomtc/ujae037.
3
Ratio and difference of average hazard with survival weight: New measures to quantify survival benefit of new therapy.平均风险与生存权重的比值和差值：量化新疗法生存获益的新指标。
Stat Med. 2023 Mar 30;42(7):936-952. doi: 10.1002/sim.9651. Epub 2023 Jan 5.
4
Moving beyond conventional stratified analysis to assess the treatment effect in a comparative oncology study.超越传统的分层分析，评估比较肿瘤学研究中的治疗效果。
J Immunother Cancer. 2021 Nov;9(11). doi: 10.1136/jitc-2021-003323.
5
Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve.利伐沙班在心房颤动合并生物瓣二尖瓣患者中的应用。
N Engl J Med. 2020 Nov 26;383(22):2117-2126. doi: 10.1056/NEJMoa2029603. Epub 2020 Nov 14.
6
Statistical Test/Estimation Methods Used in Contemporary Phase III Cancer Randomized Controlled Trials with Time-to-Event Outcomes.当代癌症 III 期随机对照试验中具有时间事件结局的统计检验/估计方法。
Oncologist. 2020 Feb;25(2):91-93. doi: 10.1634/theoncologist.2019-0464. Epub 2019 Nov 19.
7
Moving beyond the conventional stratified analysis to estimate an overall treatment efficacy with the data from a comparative randomized clinical study.超越传统的分层分析，利用来自比较随机临床研究的数据来估计整体治疗效果。
Stat Med. 2019 Mar 15;38(6):917-932. doi: 10.1002/sim.8015. Epub 2018 Oct 23.
8
How Do the Accrual Pattern and Follow-Up Duration Affect the Hazard Ratio Estimate When the Proportional Hazards Assumption Is Violated?当比例风险假设不成立时，累积模式和随访持续时间如何影响危害比的估计？
Oncologist. 2019 Jul;24(7):867-871. doi: 10.1634/theoncologist.2018-0141. Epub 2018 Sep 10.
9
Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab.基于血液的肿瘤突变负担可预测接受阿替利珠单抗治疗的非小细胞肺癌患者的临床获益。
Nat Med. 2018 Sep;24(9):1441-1448. doi: 10.1038/s41591-018-0134-3. Epub 2018 Aug 6.
10
Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis.超越风险比：在生存分析中量化组间差异。
J Clin Oncol. 2014 Aug 1;32(22):2380-5. doi: 10.1200/JCO.2014.55.2208. Epub 2014 Jun 30.
Zotero 插件